BROOKFIELD, NEWS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced the pricing of a public offering of $650 million principal amount of senior notes due 2036 (the “notes”), which will bear interest at a rate of 5.330% per annum. The offering is expected to close on August 20, 2025, subject to the satisfaction of customary closing conditions. The notes will be issued by Brookfield Finance Inc., an indirect wholly-owned subsidiary of Brookfield, and w ...

Core Insights - Centerspace published its 2024 ESG Report and inaugural TCFD report, emphasizing its commitment to sustainable practices in the multifamily industry [1][3] - The company met four out of five ESG goals two years ahead of schedule and improved its GRESB score from 63 to 70 [2] Group 1: ESG Commitment - Centerspace's 2024 ESG report aligns with GRI's 2024 Universal Standards and the United Nations Sustainable Development Goals [2] - The company established an ESG Committee in 2019 to lead sustainability initiatives [1] Group 2: Climate Risk Management - The inaugural TCFD report serves as a foundation for managing climate risk and aligns with industry-standard reporting frameworks [3] - Centerspace is focused on continuous improvement in disclosure and climate risk mitigation [3] Group 3: Operational Practices - The company is committed to responsible business practices, including resource stewardship, waste reduction, and energy and water conservation [4] - Centerspace operates 73 apartment communities with a total of 13,773 homes across several states [4]

Webcast and Conference Call Scheduled for 5:00 PM ETNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced that it will report second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The announcement will be followed by a webcast and conference call at 5:00 p.m. ET. The Company encourages investors, and interested parties, to listen via webcast, as th ...

- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 -- FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 - - Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% - - OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease - - Non-dilutive ...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee (CSRC) Recommends Tuspetinib Dose Escalation to 160 mg Dose Hanmi Continues to Support Development of Tuspetinib SAN DIEGO and TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tus ...

Q2 2025 Revenue of $26.9 millionQ2 2025 Net loss of $13.3 millionQ2 2025 Adjusted EBITDA loss of $2.4 million All figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced its financial results for the three-month period ended June 30, 2025. Planet 13’s financial statements are prepared ...

Core Insights - SCYNEXIS, Inc. reported financial results for Q2 2025, highlighting progress in its drug development pipeline and ongoing disputes with GSK regarding milestone payments [1][5][9]. Drug Development Progress - The company is advancing its second-generation fungicide candidate, SCY-247, with Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data expected to be announced in Q3 2025 [2][7]. - Positive preclinical efficacy data for SCY-247 was presented at the ESCMID meeting, showcasing its potential against difficult-to-treat fungal infections [4]. - The first new patient was dosed in the Phase 3 MARIO study after the FDA lifted the clinical hold, triggering a $10 million milestone payment from GSK [5][6]. Financial Performance - For Q2 2025, SCYNEXIS reported revenue of $1.4 million, up from $0.7 million in Q2 2024, primarily from the GSK License Agreement [9]. - Research and development expenses increased to $7.1 million in Q2 2025 from $6.8 million in Q2 2024, driven by higher costs in chemistry, manufacturing, and controls [10]. - Selling, general, and administrative expenses rose to $3.8 million in Q2 2025, a 20% increase from $3.2 million in Q2 2024, mainly due to higher professional fees [11]. - The net loss for Q2 2025 was $6.9 million, or $(0.14) per share, compared to a net loss of $14.5 million, or $(0.30) per share in Q2 2024 [13]. Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $46.5 million, down from $75.1 million at the end of 2024, providing a cash runway into Q4 2026 [14]. Legal Developments - The U.S. District Court granted SCYNEXIS's motion to dismiss a securities class action lawsuit filed in November 2023, allowing the plaintiff to amend the complaint within 30 days [8]. Corporate Strategy - SCYNEXIS is working to transfer the New Drug Application for Brexafemme to GSK by the end of 2025, enabling GSK to initiate regulatory discussions for the product's relaunch [6][16].

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the second quarter ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below). Q2 2025 Financial Highlights Total revenue increased 5.4% to $14.2 million, primarily due to organic connection g ...

Core Insights - Crescent Capital BDC reported net investment income of $0.46 per share and net income of $0.41 per share for the quarter ended June 30, 2025, with a net asset value (NAV) per share of $19.55 [1][4] Financial Performance - Total investment income increased to $43.0 million for the quarter ended June 30, 2025, compared to $42.1 million for the previous quarter [6] - Net investment income for the quarter was $16.9 million, slightly up from $16.6 million in the prior quarter [4][6] - The company experienced net realized losses of $2.9 million and a net change in unrealized gains of $1.0 million for the quarter [4][6] Dividend Declarations - The Board declared a regular cash dividend of $0.42 per share for the third quarter of 2025, payable on October 15, 2025 [2] - A special dividend of $0.05 per share will be paid on September 15, 2025 [2] Share Repurchase Program - The Board authorized a stock repurchase program to buy back up to $20.0 million of common stock in the open market [3] Investment Portfolio - As of June 30, 2025, the company had investments in 187 portfolio companies with a fair value of $1,600.7 million [5] - The portfolio consisted primarily of unitranche first lien loans, making up 65.2% of the total investments [5] Liquidity and Capital Resources - The company had $26.1 million in cash and cash equivalents and $227.2 million of undrawn capacity on its credit facilities as of June 30, 2025 [8] - The weighted average cost of debt was 6.09%, with a debt to equity ratio of 1.23x [8] Upcoming Events - A conference call to discuss the financial results for the quarter ended June 30, 2025, is scheduled for August 14, 2025 [9]

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an ind ...